IL149280A0 - Methods, kits and compositions for using pyrrole derivatives - Google Patents

Methods, kits and compositions for using pyrrole derivatives

Info

Publication number
IL149280A0
IL149280A0 IL14928002A IL14928002A IL149280A0 IL 149280 A0 IL149280 A0 IL 149280A0 IL 14928002 A IL14928002 A IL 14928002A IL 14928002 A IL14928002 A IL 14928002A IL 149280 A0 IL149280 A0 IL 149280A0
Authority
IL
Israel
Prior art keywords
kits
compositions
methods
compound
pyrrole derivatives
Prior art date
Application number
IL14928002A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL149280A0 publication Critical patent/IL149280A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14928002A 2001-04-30 2002-04-22 Methods, kits and compositions for using pyrrole derivatives IL149280A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28754501P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
IL149280A0 true IL149280A0 (en) 2002-11-10

Family

ID=23103396

Family Applications (2)

Application Number Title Priority Date Filing Date
IL204665A IL204665A (en) 2001-04-30 2002-04-22 Use of 2-(7-chloro-1, 8 -naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone and 2-(7-chloro-1, 8 - naphthyridine-2-yl) -3-(5-methyl-5-hydroxy-2-oxohexyl)-1-isoindolinone or a pharmaceutically acceptabla salt or optical isomer thereof in the preparation of medicaments for the curative, palliative or prophylactic treatment of obsessive-compulsive disorder
IL14928002A IL149280A0 (en) 2001-04-30 2002-04-22 Methods, kits and compositions for using pyrrole derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL204665A IL204665A (en) 2001-04-30 2002-04-22 Use of 2-(7-chloro-1, 8 -naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone and 2-(7-chloro-1, 8 - naphthyridine-2-yl) -3-(5-methyl-5-hydroxy-2-oxohexyl)-1-isoindolinone or a pharmaceutically acceptabla salt or optical isomer thereof in the preparation of medicaments for the curative, palliative or prophylactic treatment of obsessive-compulsive disorder

Country Status (20)

Country Link
US (2) US7026332B2 (pl)
EP (2) EP1642576B1 (pl)
JP (1) JP2002326934A (pl)
KR (1) KR20020084413A (pl)
CN (1) CN1384104A (pl)
AT (2) ATE331513T1 (pl)
AU (1) AU783516B2 (pl)
CA (1) CA2383599C (pl)
CY (1) CY1109129T1 (pl)
DE (2) DE60212757T2 (pl)
DK (1) DK1642576T3 (pl)
ES (2) ES2323646T3 (pl)
HU (1) HU228826B1 (pl)
IL (2) IL204665A (pl)
MY (1) MY129575A (pl)
NZ (1) NZ518615A (pl)
PL (2) PL207738B1 (pl)
PT (1) PT1642576E (pl)
TW (1) TWI302455B (pl)
ZA (1) ZA200203347B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633360A1 (en) * 2003-05-16 2006-03-15 Pfizer Products Incorporated Treatment of psychotic and depressive disorders
CA2525868A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
AU2004271800A1 (en) * 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
JP2007505095A (ja) * 2003-09-12 2007-03-08 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー うつ病及び不安障害の治療のためのアルファ−2−デルタリガンド及びssri及び/又はsnriを含む組み合わせ
WO2005105061A2 (en) * 2004-04-14 2005-11-10 Indevus Pharmaceuticals, Inc. Transdermal patch
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2012116288A1 (en) * 2011-02-25 2012-08-30 Concert Pharmaceuticals Inc. 2-amino-naphthyridine derivatives
CA3132810A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of fybromyalgia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607503B1 (fr) 1986-12-02 1989-02-24 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3814022A1 (de) 1988-04-26 1989-11-09 Davy Mckee Ag Verfahren zur herstellung linearer polyester, insbesondere fuer filme und folien
EP0521622B1 (en) 1991-07-03 1997-08-13 PHARMACIA & UPJOHN COMPANY Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
FR2678934B1 (fr) 1991-07-12 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2678932B1 (fr) 1991-07-12 1993-09-24 Rhone Poulenc Rorer Sa Procede de preparation des isomeres optiques d'un derive de l'amino-2 naphtyridine.
FR2681068B1 (fr) 1991-09-09 1993-11-19 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2684673B1 (fr) 1991-12-04 1994-01-21 Rhone Poulenc Rorer Sa Procede de preparation d'un derive de l'amino-2 naphtyridine racemique.
FR2687154B1 (fr) * 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
FR2695389B1 (fr) 1992-09-08 1994-11-04 Rhone Poulenc Rorer Sa Nouveau dérivé de l'isoindolinone, sa préparation et les compositions pharmaceutiques qui le contiennent.
US5498716A (en) * 1994-01-12 1996-03-12 Rhone-Poulenc Rorer S.A. 2-amino naphthyridine derivative, its preparation and its use
GB2305859A (en) * 1996-03-29 1997-04-23 Lilly Co Eli Treatment of obsessive-compulsive disorder
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
AU6381000A (en) * 1999-07-29 2001-02-19 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function

Also Published As

Publication number Publication date
IL204665A (en) 2011-05-31
KR20020084413A (ko) 2002-11-07
AU783516B2 (en) 2005-11-03
NZ518615A (en) 2004-03-26
CA2383599C (en) 2006-10-31
EP1642576A2 (en) 2006-04-05
EP1254660B1 (en) 2006-06-28
HUP0201394A2 (hu) 2002-12-28
ES2323646T3 (es) 2009-07-22
US20060128746A1 (en) 2006-06-15
US7026332B2 (en) 2006-04-11
DE60231568D1 (de) 2009-04-23
HU228826B1 (en) 2013-05-28
ATE424820T1 (de) 2009-03-15
CY1109129T1 (el) 2014-07-02
ES2267943T3 (es) 2007-03-16
ATE331513T1 (de) 2006-07-15
US7553847B2 (en) 2009-06-30
PL390683A1 (pl) 2010-05-24
EP1254660A2 (en) 2002-11-06
DE60212757T2 (de) 2007-06-28
EP1254660A3 (en) 2003-03-26
PL207738B1 (pl) 2011-01-31
PT1642576E (pt) 2009-05-21
JP2002326934A (ja) 2002-11-15
PL353681A1 (en) 2002-11-04
CN1384104A (zh) 2002-12-11
EP1642576A3 (en) 2007-01-10
DE60212757D1 (de) 2006-08-10
EP1642576B1 (en) 2009-03-11
HK1094307A1 (en) 2007-03-30
HUP0201394A3 (en) 2003-12-29
US20030022915A1 (en) 2003-01-30
ZA200203347B (en) 2003-11-26
AU2760902A (en) 2002-10-31
DK1642576T3 (da) 2009-04-14
MY129575A (en) 2007-04-30
TWI302455B (en) 2008-11-01
PL207725B1 (pl) 2011-01-31
CA2383599A1 (en) 2002-10-30
HU0201394D0 (pl) 2002-06-29

Similar Documents

Publication Publication Date Title
HUS2100028I1 (hu) ERBB I. típusú receptor tirozinkináz-gátló N4-fenil-kinazolin-4-amin származékok és rokon vegyületeik a hiperproliferatív betegségek kezelésére
ATE440603T1 (de) 8-hydroxychinolinderivate
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
NO20060408L (no) Fremgangsmate for a modulere kalsium ione-frigjorings- aktivert kalsium ionekanaler
WO2006110816A3 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
SE9900100D0 (sv) New compounds
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
ATE522509T1 (de) Pyrimidylcyclopentane als inhibitoren der akt- proteinkinase
MXPA04006184A (es) Compuestos derivados de 1h-pirazolilo, para el uso en enfermedades asociadas con el receptor 5-ht2c.
ATE277072T1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
CY1109129T1 (el) Χρηση παραγωγων πυρρολιου για καταπολεμηση του αγχους
WO2003057213A3 (en) Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
ATE407923T1 (de) Tyrosinderivate als phosphatase inhibitoren
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
AU2002364711A1 (en) Substituted 5-hydroxy-indole compounds for the treatment of glaucoma
AU2002214657A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
ZA200400824B (en) Pyridin-2-yl-methlyamine derivatives for treating opioid dependence.
DE50307080D1 (de) Verfahren zur herstellung von norgalanthamin, ihren isomeren, salzen und hydraten

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees